Trial
NCT03837353
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
NYU Langone Health
Collaborators
Leap Therapeutics, Inc.
Condition
Prostate Cancer
Intervention
DKN-01
Why stopped
Terminated early due to slow accrual in the context of changing practice patterns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-18